drugset / Trial / NCT02303418

Carbetocin Versus Oxytocin in the Prevention of Post Partum Haemorrhage (PPH) in Women Undergoing Caesarean Sections for Placenta Previa: A Randomised Controlled Trial

NCT02303418

Phase 3 Unknown 500 enrolled Cairo University
RandomizedParallel-groupTriple-blindPrevention

Summary

The study aims at comparing the roles of carbetocin and oxytocin in the prevention of atonic PPH in women undergoing CS for placenta previa. 200 women will be randomly divided into 2 equal groups using computer generated random numbers, Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland).

Timeline

Start
2014-11
Primary completion
2017-11
Completion

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carbetocin Peptide 100 ug Intravenous
Comparator Oxytocin Peptide 5 iu Intravenous

Indications

No indication recorded.